BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Scaling New Levels: Rock Climbing Spots On the planet - 2'We are ready': NASA still on track to launch Artemis 2 astronauts to the moon April 1
- 3Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
- 4From Modesty to Administration: Self-improvement in Interactive abilities
- 5Launch pad damaged as Russian rocket blasts off for space station, agency says
- Italian authorities detain civilian rescue ship, German NGO says
- Palestinians tell BBC they were sexually abused in Israeli prisons
- Living in the dark: Gaza’s struggle for electricity
- Israel's fractured opposition hands Netanyahu a full term
- 'It's doing badly': Fears grow for whale stuck off Germany's coast
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- 5 VIP Voice Exhibitions in Energized Movies
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- 6 Fledgling Cameras for 2024: Ideal for New Photographic artists
